Skip to main content

Acute Coronary Syndrome News (Page 2)

FDA Approves Expanded Indication for Brilinta to Include Long-Term Use in Patients with a History of Heart Attack

Thursday, 3 September 2015 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Brilinta (ticagrelor) tablets at a new 60mg dose to be used in patients with a...

Medicure Announces Approval of Expanded Dosing Time For Aggrastat

WINNIPEG, April 23, 2015 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the United States Food and...

FDA Approves New Crushing Option for the Administration of Brilinta

March 30, 2015 – AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved a new administration option for acute coronary syndrome (ACS) patients who are...

FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes

July 20, 2011 - The U.S. Food and Drug Administration today approved the blood-thinning drug Brilinta (ticagrelor) to reduce cardiovascular death and heart attack in patients with acute coronary...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Coronary Artery Disease (CAD)

Related drug support groups

Plavix, clopidogrel, Brilinta, Lovenox, ticagrelor